HealthDay News - FDA approved 13-valent pneumococcal conjugated vaccine (PCV13, Prevnar 13, Wyeth Pharmaceuticals) for people aged 50 years and older. Vaccine goal bacterial pneumonia and other diseases caused by 13 serotypes of the pathogen of pneumonia Streptococcus, and has been approved for children aged 6 weeks to 5 years for prevention of invasive disease and otitis media, according to a press release agency buy strattera online. New evidence was given by the use of accelerated approval, which allows manufacturers of drugs used immune marker that shows enough clinical benefit for serious or life-threatening conditions, FDA said. In clinical trials for a wide use of vaccines, people 50 years and older were either present PCV13 or other licensed vaccines pneumonia, 23-valent vaccine pneumococcalpolysaccharide (PPSV23, Pneumovax 23, Merck). The results indicated PCV13 induced levels of antibodies of the immune system that are or have been compared to or greater than those associated with PPSV23. Patients showed a similar profile of adverse events with both vaccines, the most common including injection site swelling, redness and pain, fatigue, headache, chills, muscle aches and joint pain. Another after approval of research involving 85,000 people aged 65 and older continues to verify the clinical effect under fast-track approval, according to FDA. For more information, the U.S. Centers for Disease Control and Prevention has more. .
No comments:
Post a Comment